The price of Inhibikase Therapeutics Inc. (NASDAQ:IKT) shares last traded on Wall Street rose 21.28% to $0.91.
Based on available information, 1 analysts follow Inhibikase Therapeutics Inc. (NASDAQ:IKT). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.75, this indicates a potential upside of 700.0 percent. IKT stock price is now 58.81% away from the 50-day moving average and 11.49% away from the 200-day moving average. The market capitalization of the company currently stands at $22.08M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
.
In other news, Werner Milton H., President and CEO bought 5,000 shares of the company’s stock on Aug 16. The stock was bought for $4,000 at an average price of $0.80. Upon completion of the transaction, the President and CEO now directly owns 5,335,433 shares in the company, valued at $4.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 27, President and CEO Werner Milton H. bought 5,000 shares of the business’s stock. A total of $4,880 was incurred on buying the stock at an average price of $0.98. This leaves the insider owning 5,330,433 shares of the company worth $4.85 million. A total of 21.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IKT stock. A new stake in Inhibikase Therapeutics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $22,000. MILLENNIUM MANAGEMENT LLC invested $15,000 in shares of IKT during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Inhibikase Therapeutics Inc. valued at approximately $7,000. In total, there are 25 active investors with 18.30% ownership of the company’s stock.
A candlestick chart of Inhibikase Therapeutics Inc. (NASDAQ: IKT) showed a price of $0.7880 on Tuesday morning. During the past 12 months, Inhibikase Therapeutics Inc. has had a low of $0.44 and a high of $1.52. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.70, and a quick ratio of 8.70. The fifty day moving average price for IKT is $0.5730 and a two-hundred day moving average price translates $0.8163 for the stock.
The latest earnings results from Inhibikase Therapeutics Inc. (NASDAQ: IKT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.18, beating analysts’ expectations of -$0.19 by 0.01. This compares to -$0.18 EPS in the same period last year. The company reported revenue of $7000.0 for the quarter, compared to $0.33 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -97.87 percent. For the current quarter, analysts expect IKT to generate $200k in revenue.
Inhibikase Therapeutics Inc.(IKT) Company Profile
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
